BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07), Briefing.com reports. The firm had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same period last year, the business posted ($0.19) EPS. The company’s revenue was up 35.1% on a year-over-year basis.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded down $0.11 during mid-day trading on Tuesday, reaching $7.24. 1,236,664 shares of the company’s stock were exchanged, compared to its average volume of 2,966,223. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -11.87 and a beta of 1.89. The firm has a 50-day moving average price of $7.84 and a two-hundred day moving average price of $6.95. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BCRX. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. JMP Securities boosted their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $14.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.